CD22 and acute lymphoblastic leukemia: Furthermore, Myers et al. presented the results of a phase 1 trial evaluating novel CD22/4-1 BB CAR T-cells using a short scFv linker and called CART22-65s in patients with relapsed CD19-negative B-ALL after failure of CD19-targeted CAR T-cells (NCT02650414).